Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • US R&D investment

    - PMLiVE

    Amgen agrees to lower prescription drug costs in deal with US government

    The company has invested $40bn in US R&D and manufacturing in the past seven years

    - PMLiVE

    Gilead agrees on affordable medicines plan with US government

    The company recently announced a $32bn investment in US R&D and manufacturing

    - PMLiVE

    Novartis agrees to lower drug prices in deal with US government

    In 2025, the pharma company announced a $23bn US investment commitment

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    AstraZeneca announces agreement with US government to reduce medicine costs

    The pharma company is the latest to offer direct-to-consumer purchasing

    - PMLiVE

    Pfizer agrees pricing and distribution deal with US government

    The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

    The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links